Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLO-AML 1
2010-023499-25Phase 2Terminated
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of volasertib and cytarabine in acute myeloid leukemia (AML) (2 arms). Primary endpoints: Complete remission and Overall survival. Started May 2011; status: terminated.
02
Drugs
volasertibcytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2010-023499-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023499-25.